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Hemophilia A is an inherited coagulation disorder resulting in the loss of functional
clotting factor VIII (FVIII). Presently, the most effective treatment is prophylactic protein
replacement therapy. However, this requires frequent life-long intravenous infusions of
plasma derived or recombinant clotting factors and is not a cure. A major complication
is the development of inhibitory antibodies that nullify the replacement factor. Immune
tolerance induction (ITI) therapy to reverse inhibitors can last from months to years,
requires daily or every other day infusions of supraphysiological levels of FVIII and is
effective in only up to 70% of hemophilia A patients. Preclinical and recent clinical
studies have shown that gene replacement therapy with AAV vectors can effectively
cure hemophilia A patients. However, it is unclear how hemophilia patients with high
risk inhibitor F8 mutations or with established inhibitors will respond to gene therapy,
as these patients have been excluded from ongoing clinical trials. AAV8-coF8 gene
transfer in naïve BALB/c-F8e16−/Y mice (BALB/c-HA) results in anti-FVIII IgG1 inhibitors
following gene transfer, which can be prevented by transient immune modulation with
anti-mCD20 (18B12) and oral rapamycin. We investigated if we could improve ITI
in inhibitor positive mice by combining anti-mCD20 and rapamycin with AAV8-coF8
gene therapy. Our hypothesis was that continuous expression of FVIII protein from
gene transfer compared to transient FVIII from weekly protein therapy, would enhance
regulatory T cell induction and promote deletion of FVIII reactive B cells, following
reconstitution. Mice that received anti-CD20 had a sharp decline in inhibitors, which
corresponded to FVIII memory B (Bmem) cell deletion. Importantly, only mice receiving
both anti-mCD20 and rapamycin failed to increase inhibitors following rechallenge with
intravenous FVIII protein therapy. Our data show that B and T cell immune modulation
complements AAV8-coF8 gene therapy in naïve and inhibitor positive hemophilia A mice
and suggest that such protocols should be considered for AAV gene therapy in high risk
or inhibitor positive hemophilia patients.
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INTRODUCTION
Hemophilia, a hereditary monogenic x-linked inherited
coagulation disorder, is defined by a loss in functional
coagulation factor VIII (FVIII), hemophilia A, or factor IX
(FIX), hemophilia B, proteins. Hemophilia A is approximately
four times more common than hemophilia B with indices of 1
in 5,000 and 1 in 20,000 male births, respectively. Patients are
classified as severe, moderate, or mild depending on residual
coagulation factor activity and are at risk for developing
spontaneous (severe) and trauma induced bleeds (moderate and
mild) (1). Often bleeds occur in joints and results in hemarthrosis
with significant morbidity. Bleeds into closed spaces, such as the
cranium, that are not managed, result in mortality (2).
Hemophilia is presently treated on-demand or
prophylactically with intravenous infusion of plasma derived or
recombinant factor protein (3). More recently, extended half-life
FVIII and FIX products have been made available, reducing
the frequency of infusions (4). However, the development
of anti-drug antibodies, termed inhibitors, remains a major
complication in therapy. Inhibitor incidence is much higher
in hemophilia A patients at 25–30%, whereas only 3–5% of
hemophilia B patients go on to develop inhibitors (5). Often
inhibitors occur in patients with severe disease, in which there is
little or no expressed clotting factor. Inhibitors develop within
the first year or two of starting protein therapy, often by 20
exposure days, and the relative risk of inhibitor formation is
reduced with successive event free clotting factor infusions or
exposure days (6).
Gene replacement therapy using adeno-associated virus
(AAV) based vectors to deliver functional F8 and F9 genes
to the liver have resulted in stable and therapeutic FVIII
and FIX protein levels in adult hemophilia patients (7), with
several candidates advancing into phase III clinical trials (8).
Importantly, no patient receiving AAV gene therapy (despite
a variability in factor protein expression levels) has developed
inhibitors (7, 9, 10). However, the outcome of AAV gene therapy
in young children with lower exposure days and in adults with
established inhibitors is presently unknown, although the latter
is scheduled to be addressed in a clinical trial (NCT03734588).
The ongoing AAV gene therapies for hemophilia are
dependent on decades long preclinical studies in genetic
knockout mice and naturally occurring canine hemophilia
animal models (11–13). Early pre-clinical studies for hemophilia
B showed that restricted expression of FIX protein to hepatocytes
resulted in stable inhibitor free expression in both murine and
canine hemophilia Bmodels with a F9 gene deletion (11). Inmice,
it was shown that hepatocyte restricted expression of FIX protein
resulted in the induction of peripheral regulatory T cells (Treg)
that suppressed the formation of inhibitory antibodies (14, 15).
Later studies demonstrated that AAV liver gene therapy and these
suppressive Treg could also eliminate inhibitors in murine and
canine hemophilia A and B models (16–18).
While these studies suggest that gene therapy could be
administered to patients with established inhibitors, it is
unknown whether there is an inhibitor threshold above which
gene therapy could be rendered ineffective. Combinatorial
treatment with gene therapy and drugs such as rituximab could
potentiate inhibitor elimination, thus preventing neutralization
of the newly expressed clotting factor. Immune tolerance
induction with rituximab as single-agent therapy has shown
mixed responses in inhibitor patients (19, 20), with a main
mechanism of action being memory B cell depletion (21). We
have previously shown that combining a murine equivalent of
rituximab (anti mouse CD20) with the T cell targeting drug,
rapamycin can effectively reduce inhibitors in hemophilia Amice
(22). We therefore applied this combination treatment regimen
to gene therapy for hemophilia A in mice with established
inhibitors for this study.
MATERIALS AND METHODS
Mice
All animals used at initiation of experiments were 8 to 10-
week-old male mice on the BALB/c [H-2d], C3H/HeJ [H-
2k], or B6;129S [mixed H-2b] background. Wild type mice
were purchased from Jackson Laboratories (Bar Harbor, ME).
Hemophilia A mice with a deletion in exon 16 of the F8 gene
(BALB/c F8e16−/Y) were kindly provided by Dr. David Lillicrap
(Queens, Ontario, Canada). Hemophilia B mice with a targeted
deletion of murine F9 have been bred on BALB/c background
for >10 generations (14). B6;129S-F8tm1Kaz (B6;129S-HA) mice
(23) were purchased from Jackson Laboratories (Bar Harbor,ME)
stock number 004424 and bred in house.
Animals were housed under specific pathogen-free conditions
at the University of Florida Animal Care Service facility
and Indiana University laboratory animal resources center
(LARC). Food and water were given ad libitum. Animals were
treated under Institutional Animal Care and Use Committee-
approved protocols.
Viral Vectors
For FIX gene therapy, we used AAV8-ApoE/hAAT-hF9, which
carries the hepatocyte-specific expression cassette for hFIX
(24). This cassette includes an apolipoprotein E (ApoE)
enhancer/hepatocyte control region, a human a1-antitrypsin
promoter, hFIX cDNA, a 1.4-kb portion of intron 1 of the
F9 gene, and the bovine growth hormone poly(A) signal. For
FVIII gene therapy, we used the AAV8-ApoE-hAAT-cohBDD-
F8 vector, using a codon-optimized, human B-domain deleted F8
(cohBDD-F8) gene, which has been shown to enhance the levels
of transcribed FVIII protein (25). AAV serotype 8 vectors were
produced as previously described (26–28).
Reagents
Recombinant human B domain deleted (BDD) FVIII (Xyntha)
was from Pfizer (New York, NY). FVIII and FIX deficient plasma
was from Haematologic Technologies (Essex Junction, VT).
Anti-mCD20 IgG2a subtype (clone 18B12) was purified from
transfected HEK293 cells (ATUM, Newark, CA). Rapamycin was
purchased from LC laboratories (Woburn, MA). Keyhole limpet
hemocyanin was purchased from Sigma Aldrich (St. Louis, MO).
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Inhibitor Establishment and Gene Therapy
Tolerance Regimen
For establishment of a tolerance regimen to prevent the
development of FVIII inhibitors to gene therapy, naïve BALB/c
F8e16−/Y mice were administered 1 × 1011 vg AAV8-ApoE-
hAAT-cohBDD-F8 vector, using the IV route, and divided into 4
cohorts. Cohort 1 were control mice that received vector without
immune suppression. Cohorts 2–4 received immune suppression
along with vector. Cohort 2 received two IV doses of 250 µg
anti-mCD20 (with vector and 3 weeks later). Cohort 3 received
4 mg/kg rapamycin (3x/week) by oral gavage 2 weeks after vector
administration for 4 weeks. Cohort 4 received a combination of
anti-mCD20 and rapamycin. Mice from cohorts 1 and 4 were
further challenged with weekly IV injections for 4 weeks with
1.5 IU BDD FVIII protein (Xyntha, Pfizer) at 8 weeks following
treatment. To show that mice receiving immune suppression had
an intact immune response, mice were IV injected with 100µg of
keyhole limpet hemocyanin (KLH) at 14 weeks post-AAV gene
transfer and bled 3 weeks later to measure anti-KLH IgG1 levels
in plasma by Enzyme linked immunosorbent assay (ELISA).
For reversal studies, high titer inhibitors were initially
established in naïve BALB/c F8e16−/Y mice by administering
weekly IV injections of 1.5 IU BDD FVIII protein for 4 weeks.
This was followed by gene therapy with 1× 1011vg AAV8-ApoE-
hAAT-cohBDD-F8 vector and either anti-mCD20, rapamycin, or
the combination immunosuppressive regimen was administered
as indicated. Follow up analysis was carried out for a further 2
months, following which, mice were re-challenged further with
weekly IV injections of 1.5 IU BDD FVIII protein for 4 weeks.
Adoptive Transfer of Treg and FVIII Antigen
Challenge
Splenocyte isolation and Treg enrichment was performed as
previously described (29). Briefly, spleen cells from various
treatment groups were isolated and enriched following the
instructions of the mouse Treg isolation kit from Miltenyi
Biotec (Carlsbad, CA). In our hands, Treg enrichment with
this kit typically gives a purity of 80–90% confirmed by flow
cytometry staining of CD4+ CD25+ FoxP3+ cells. Naïve BALB/c
F8e16−−/Y mice received 1 × 106 Treg by tail vein injection and
were immunized with a subcutaneous injection of 1.5 IU of FVIII
protein emulsified in Sigma Adjuvant System (Millipore Sigma
S6322, St. Louis, MO). Animals were bled 3 weeks after FVIII
immunization and plasma was collected to measure anti-FVIII
IgG1 antibody levels using an ELISA assay.
Analysis of Plasma Samples
Plasma samples were collected by retro-orbital eye bleed into
0.38% sodium citrate buffer. Inhibitory antibodies to FVIII
or FIX were measured by Bethesda assay as described (16,
22). Measurements were carried out in a Diagnostica Stago
STart Hemostasis Analyser (Parsippany, NJ, USA). ELISA-based
measurements of antibodies to FVIII or FIX were carried out
as described (16, 22). FVIII or FIX activity was measured by a
one stage clotting assay based on a modified activated partial
thromboplastin time assay (aPTT) as described (16, 22). Percent
activity is an indication of the extent a plasma sample corrects the
coagulation time of FVIII or FIX deficient plasma in the assay.
Memory B Cell ELISpot
Memory B cell enzyme-linked immunospot (ELISpot) was
performed as previously described (30). Briefly, spleen cells from
various treatment groups were isolated and depleted of CD138+
antibody secreting plasma cells using anti-CD138 microbeads
(Miltenyi Biotec, Carlsbad, CA). CD138− spleen cells were
cultured at 1.5× 106 cells/mL in RPMI 1640 (Life Technologies)
supplemented with 10% fetal calf serum (Atlanta Biologicals,
Norcross, GA), 2mM l-glutamine, 10,000 U/mL penicillin, 100
mg/mL streptomycin and 55µM β-mercaptoethanol (Sigma-
Aldrich) at 37◦C for 6 days. 0.1 IU/mL BDD-FVIII was added to
the cells on day 0 as indicated. Newly formed antibody secreting
cells (ASCs) were detected by ELISpot assays, using the CTL-
ImmunoSpot system (Shaker Heights, OH).
Flow Cytometry Studies
Peripheral blood mononuclear cells (PBMCs) were stained with
the following antibodies, B220-FITC, CD4-e450, CD8-BV510,
CD25-BV605, and FoxP3-e660 using the FoxP3 staining buffer
kit from eBioscience per manufacturer’s instructions. Data were
collected on an Attune NXT flow cytometer and cell population
analysis was conducted using FCS Express 7 (De Novo software,
Glendale, CA).
Statistical Analysis
All statistical analysis was carried out using Graph Pad Prism
software (La Jolla, CA) using Student’s 2-tailed T-test, one-way
ANOVA with Bonferroni’s multiple comparison test, or two-way
ANOVA with Tukey’s multiple comparisons test. A p < 0.05 was
considered statistically significant, and indicated as follows: ∗p <
0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p <0.0001.
RESULTS
Immune Response to Clotting Factor
Protein or Gene Therapy Is Mouse Strain
Dependent
Historically we have observed that the hemophilia B mice on a
BALB/c background are less responsive to FIX protein therapy
compared to mice on the C3H/HeJ background with an identical
F9 gene deletion (31). A previous study comparing immune
responses to recombinant full length FVIII protein therapy in
BALB/c and C57BL/6 hemophilia A mice reported that mice
on the C57BL/6 background developed a higher antibody and
inhibitor titer (32). However, more recombinant FVIII protein
products are B-domain deleted FVIII (BDD-FVIII) and clinical
gene therapy vectors also express BDD-FVIII protein. Thus, it
is important to understand potential genetic risk factors for
inhibitor formation against recombinant and vector derived
BDD-FVIII. Groups of hemophilia A mice on BALB/c (BALB/c-
HA) or B6;129S (B6;129S-HA) background received 4 weekly IV
injections of 1 IU BDD-FVIII protein. Blood was collected on
week 5 and plasma levels of anti-FVIII IgG1 and Bethesda titers
were determined. We observed significantly lower levels of both
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anti-FVIII IgG1 (Figure 1A) and Bethesda inhibitor (Figure 1B)
titers in BALB/c-HAmice. B6;129S-HAmice (n= 23) had amean
anti-FVIII IgG1 level of 3,996 ng/mL and inhibitor titer of 210
BU/mL compared to BALB/c-HA mice (n= 16) anti-FVIII IgG1
of 1,479 ng/mL and Bethesda titer of 14 BU/mL.
Based on the stronger response of B6;129S-HA mice to
recombinant BDD-FVIII protein, we hypothesized that these
mice would have a higher risk of developing inhibitors following
gene transfer of an AAV8-ApoE-hAAT-cohBDD-F8 (AAV8-
coF8) vector. To test this, we injected both hemophilia A
mouse strains with 1 × 1011 vg of the AAV8-coF8 vector and
followed mice over time. Plasma was tested at different time
points post-vector injection and was analyzed for FVIII activity,
Bethesda inhibitors, and anti-FVIII IgG1. Surprisingly, BALB/c-
HAmice developed both anti-FVIII IgG1 antibodies (Figure 1C)
and Bethesda inhibitor titers (Figure 1D) 8 weeks post-vector
administration. In contrast, B6;129S-HA mice did not develop
anti-FVIII IgG1 or Bethesda inhibitors (Figures 1C,D) and
displayedmoderate FVIII activity (Figure 1E) even after 4 weekly
challenges with recombinant BDD-FVIII protein.
Transient Immune Modulation With
Anti-CD20 and Rapamycin Combination
Therapy Prevents Inhibitors to FVIII Gene
Therapy in BALB/HA Mice
Based on these results (Figures 1C,D), we used BALB/c-HA
mice that naturally develop inhibitors following AAV8-coF8 gene
therapy to determine if our immune modulatory protocol could
prevent inhibitors and promote FVIII tolerance. Our group
has previously developed several transient immune modulatory
protocols to prevent and reverse inhibitors in the context of
FVIII protein therapy in BALB/c-HA mice (22, 25, 33, 34). Thus,
we hypothesized that transient immune modulation may be
effective at preventing inhibitors following AAV8-coF8 liver gene
transfer. Based on our previous published studies with immune
suppression in the context of protein therapy (22), we elected to
initially test a B cell depleting antibody, anti-mCD20 (250 µg) on
weeks 0 and 3 or oral rapamycin (4 mg/kg) 3 times per week from
weeks 2 through 5 post-vector administration [Figure 2A; (22,
33)]. PBMCs were collected at week 4 post-vector administration
and stained with antibodies to detect B cells (B220), CD4 and
CD8T cells, and Tregs (CD4+CD25+FoxP3+). As expected, we
observed a significant decrease in the frequency and number of
B220 positive cells in mice receiving the B cell depleting anti-
mCD20 antibody compared to vector and vector and rapamycin
treated mice (Figures 2B,C). Mice receiving the anti-mCD20
antibody had a statistically significant elevated frequency of
CD4 and CD8T cells but only had a modest elevation in
total CD4T cells. There was no significant difference in the
frequency and total number of Tregs between the different groups
(Figures 2B,C). By week 8 post-vector, the majority of mice
treated with vector alone had developed FVIII inhibitors as
measured by anti-FVIII IgG1 and Bethesda assay (Figures 2D,E).
In contrast, about half of the mice treated with AAV and
rapamycin developed inhibitors. However, one animal in this
group had the highest titer inhibitor in the whole cohort,
suggesting that rapamycin alone is not effective at preventing
inhibitors (Figures 2D,E). AAV combined with anti-mCD20 was
the most effective combination with only two animals developing
inhibitors at week 8 post-vector (Figures 2D,E). At week 12 anti-
FVIII IgG1 levels were starting to emerge in the AAV combined
with anti-mCD20 mice. However, only two animals in the group
had a detectable Bethesda inhibitor (Figures 2D,E).
To improve the effectiveness of inhibitor suppression,
we designed a study to combine both anti-mCD20 and
rapamycin along with vector administration. Mice received
weekly challenges of 1.5 IU BDD-FVIII for 4 weeks starting at 8
weeks post-vector (Figure 3A) and at the end of the challenge,
some animals were followed longer while others were used as
donors for regulatory T (Treg) cell adoptive transfer studies
into naïve BALB/c-HA mice. During the course of treatment,
blood was collected and plasma anti-FVIII IgG1 levels and
Bethesda titers were measured. Control mice receiving only
vector developed inhibitors whereas mice receiving immune
modulatory therapy with vector failed to develop inhibitors
even after immunological challenge with recombinant FVIII
protein (Figures 3B,C). Additionally, 7 out of 9 mice receiving
the immune modulation failed to mount an IgG2a antibody
response against the AAV8 capsid (29.97± 64 ng/ml) whereas all
control mice treated with vector alone formed anti-AAV8 IgG2a
antibodies (1,229± 316 ng/mL, Figure 3D).
To test if immunological tolerance was established, we isolated
Treg from the spleens of a subset of the BALB/c-HA mice
receiving either vector alone or vector with immune modulation
and adoptively transferred 1 × 106 Treg into naïve BALB/c-
HA mice, followed by subcutaneous challenge with 1.5 IU
FVIII in adjuvant. Naïve BALB/c-HA mice were also challenged
with FVIII in adjuvant to provide a baseline for the maximal
antibody response. Three of four mice receiving Treg from
vector/rapamycin/anti-mCD20 treated donors failed to generate
antibodies against FVIII protein whereas mice receiving Treg
from vector only donors were indistinguishable from control
adjuvant challenged mice (Figure 3F). This demonstrates that
transient immune suppression coupled with AAV liver gene
delivery of FVIII protein is capable of augmenting antigen
specific Treg as previously observed in the context of FVIII
protein replacement therapy (29).
Finally, in order to confirm that immune suppression
by vector/rapamycin/anti-mCD20 treatment was transient, we
administered the strong immune stimulatory T help dependent
antigen keyhole limpet hemocyanin (KLH) in mice, 2 months
after immune suppressive treatment was completed. Both
controls and mice that had previously received immune
suppressive treatment developed robust IgG1 antibody responses
to KLH (41,571 vs. 66,745 ng/mL, respectively), indicating that
B and T cell compartments had completely recovered in these
animals (Figure 3E).
Our prior work has shown that AAV-F9 liver gene transfer
alone is sufficient for elimination of anti-FIX IgE and IgG1 as
well as functional inhibitors in C3H/HeJ-HB mice (16). Here
we show that AAV8-F9 liver gene transfer is also effective at
eliminating inhibitors in BALB/c-HBmice, with the samemurine
F9 deletion (Figure S1). However, in this background, inhibitor
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FIGURE 1 | Differential immune responses to BDD-FVIII protein in hemophilia A mice on different genetic backgrounds when delivered as recombinant protein or
expressed in hepatocytes. Hemophilia A mice on B6;129 (n = 27) or BALB/c (n = 21) backgrounds received 4 weekly IV injections of 1 IU BDD-FVIII and plasma was
collected at week 5 to measure anti-FVIII IgG1 levels (A) and Bethesda inhibitor titers (B). In some animals we were unable to measure Bethesda inhibitors due to
technical issues. Hemophilia A mice on 129;B6 or BALB/c backgrounds (n = 4 per strain) were IV injected with 1 × 1011 vg AAV8-ApoE-hAAT-coF8 vector and
followed over time for anti-FVIII IgG1 levels (C), Bethesda inhibitor titers (D), and one-stage aPTT activity assay (E). Mice were rechallenged with weekly IV injections of
1 IU BDD-FVIII protein for 4 weeks (C–E). Statistical analysis of (A,B) was performed using 2-tailed Mann-Whitney test and (C–E) with multiple row T-test. A p < 0.05
was considered statistically significant, and indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
induction required subcutaneous injection of FIX protein in
adjuvant as the majority of mice failed to develop significant anti-
FIX IgG1 levels following recombinant FIX protein challenge
with 10 IU FIX protein [Figure S1A; (31)]. A vector dose
of 1 × 1010 vg failed to reverse inhibitors in contrast to
what we had reported in C3H/HeJ-HB mice, although this
result is not unexpected as a previous study demonstrated
that successful inhibitor reversal in adjuvant-FIX challenged
mice with a lentiviral vector required higher FIX expression
levels (12). However, a higher vector dose of 1 × 1011 vg
led to the rapid elimination of inhibitors (Figures S1B,C) and
therapeutic levels of hFIX protein (Figure S1D). Over time, FIX
levels in inhibitor positive BALB/c-HB mice converged with
naïve BALB/c-HB treated with the same vector dose. Thus,
these data demonstrate that mice on a BALB/c background are
responsive to AAV liver mediated tolerance induction despite
a previous report which claimed impaired tolerance in this
background (35).
Anti-CD20 and Rapamycin Therapy
Tolerizes FVIII Gene Therapy in BALB/c HA
Mice With Established Inhibitors
After establishing that anti-CD20 and rapamycin treatment
complements AAV8-coF8 liver gene transfer, we next asked if
this combined therapy would be effective for ITI. To induce
inhibitors, BALB/c-HA mice received 4 weekly IV injections of
1.5 IU BDD-FVIII protein and animals were bled and tested
for anti-FVIII IgG1 and Bethesda titers. Mice were then divided
into four groups: (1) vector alone, (2) vector plus rapamycin,
(3) vector plus anti-mCD20, and (4) vector plus rapamycin
and anti-mCD20, in which each group contained a similar
range of inhibitor titers (Figure 4A). To determine if tolerance
was established, BALB/c-HA mice received an additional 4
weekly injections of 1.5 IU BDD-FVIII protein at week 13
post-vector and were bled the following week. Mice in the
vector only and vector and rapamycin treatment groups had an
increase in both anti-FVIII IgG1 and Bethesda inhibitor titers
(Figures 4B,C), whereas mice in the vector/anti-mCD20 and
vector/rapamycin/anti-mCD20 groups had an initial decrease
in both anti-FVIII IgG1 (Figure 4B) and Bethesda inhibitor
titers (Figure 4C). We observed a significant decrease in anti-
FVIII IgG1 levels in animals receiving immune suppression
compared to only vector at weeks 4 and 17 and at all
time points in mice receiving anti-mCD20 and rapamycin. A
significant decrease in Bethesda inhibitor titers was observed at
weeks 8 and 17 in all animals receiving immune suppression.
However, only mice receiving vector/rapamycin/anti-mCD20
maintained their reduced anti-FVIII IgG1 and Bethesda inhibitor
titers following BDD-FVIII protein challenge (Figures 4B,C).
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FIGURE 2 | Prophylactic immune suppression with anti-mCD20 or rapamycin is only partially effective at preventing inhibitors. BALB/c-HA mice were divided into
three groups (n = 8 per group), control (red), rapamycin (green), and anti-mCD20 (blue). All groups were IV injected with 1 × 1011 vg of the AAV8-coF8 vector.
Treatment and blood collection time points are indicated in the timeline (A). Flow cytometry staining of PBMCs was performed at week 4 to stain for B cells (B220+),
CD4T cells (CD4+), CD8T cells (CD8+), and Treg (CD4+ CD25+ FoxP3+), and data is reported as frequency of PBMCs (B) and total cell counts (C). Anti FVIII IgG1
levels (D) and Bethesda inhibitor titers (E) over time. A p < 0.05 was considered statistically significant, and indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001.
Overall, the average fold reduction in Bethesda titers in
response to the treatment regimen was consistently higher
for the vector/rapamycin/anti-mCD20 group (3.8 to 8.2-fold
reduction, weeks 8–17), as compared to the vector/anti-mCD20
group (0.43 to 2.2-fold reduction, weeks 8–17, Figure 4D).
Importantly, inhibitors failed to recover in the triple treated
group when rechallenged with intravenous FVIII protein
therapy. However, despite the reduction in inhibitor titers in
the vector/rapamycin/anti-mCD20 group, we were unable to
detect any functional correction in hemostasis in any of the
treated animals using a two-stage chromogenic assay (data
not shown).
Importantly, both the vector/anti-mCD20 and vector/
rapamycin/anti-mCD20 treatment regimens reduced the
formation of IgG2a antibodies to the AAV8 capsid (103 and
116 ng/mL, respectively). Mice treated with vector only or with
vector/rapamycin developed anti-AAV8 IgG2a antibodies (988
and 888 ng/mL, respectively) that would theoretically preclude
successful re-administration of the vector (Figure 4E).
Since only animals treated with the B cell depleting antibody,
anti-mCD20 (alone or in combination with rapamycin), showed
a reduction in inhibitors, we hypothesized that this was likely
due to the elimination of anti-FVIII IgG1+ memory B cells. Our
previous studies in BALB/c and BALB/c-HA mice demonstrated
that a substantial fraction of the B cell compartment is eliminated
following anti-mCD20 treatment (22). During the course of
B cell maturation, a subset of cells become memory B cells
capable of rapidly responding to secondary exposure to antigen
(36). Importantly, it has been shown that FVIII specific IgG1+
memory B cells require the presence of activated T cells and
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FIGURE 3 | Prophylactic immune suppression with anti-mCD20 and rapamycin prevents inhibitors following AAV8-coF8 gene delivery in BALB/c-HA mice.
BALB/c-HA mice were divided into two groups (n = 8 per group), control (blue) and anti-mCD20 plus rapamycin treated (red). (A) Both groups were IV injected with 1
× 1011 vg AAV8-coF8 vector as indicated in the experimental timeline. Mice receiving immune suppression received anti-mCD20 along with vector and 3 weeks later.
Oral gavage of rapamycin was started 2 weeks after vector, three times per week for 4 weeks. Mice received weekly IV injections of 1.5 IU FVIII starting at week 8 for 4
weeks. Mice were followed over time for anti-FVIII IgG1 levels (B), and Bethesda inhibitor titers (C). Plasma from mice at 8 weeks post-vector was used to measure
anti-AAV8 IgG2a antibody levels by ELISA (D). The surviving mice AAV only (n = 3) and AAV with immunosuppression (n = 4) were challenged with KLH to show that
the transient immunosuppression did not compromise adaptive immunity and anti-KLH IgG1 levels were measured by ELISA (E). Treg were isolated from four mice in
each treatment group and 1 × 106 Tregs were adoptively transferred into naïve BALB/c-HA mice and the next day mice (Treg transfer and naïve controls) were
challenged with subcutaneous delivery of 1.5 IU FVIII protein in adjuvant and bled 2 weeks later to measure anti-FVII IgG1 antibody levels by ELISA (F). Statistical
analysis of (D) was performed using unpaired T-test with ****p < 0.0001.
antigen in order to differentiate into antibody producing plasma
cells (37). To test this hypothesis, we isolated splenocytes from
the surviving BALB/c-HA mice of each group to look at the
frequency of FVIII specific memory B cells. Plasmablasts and
plasma cells were depleted using anti-CD138 magnetic beads
and the remaining splenocytes were cultured for 6 days with or
without 0.1 IU/mL BDD-FVIII protein (16, 30, 37). Following
re-stimulation, the cells were plated for a FVIII specific B cell
ELISpot assay. All mice treated with anti-mCD20 were negative
for FVIIImemory B cells whereasmice from the other two groups
that received vector alone or vector and rapamycin developed
FVIII ASCs only upon antigen re-stimulation (Figure 4F). To
verify these results we conducted an additional study to expand
the group of vector/anti-mCD20 and vector/rapamycin/anti-
mCD20 animals and again observed an absence of FVIII memory
B cells, whereas control mice immunized with intravenous
delivery 1.5 IU recombinant FVIII protein had a substantial
population of FVIII specific memory B cells (Figure S2). Overall,
our results suggest that elimination of memory B cells is
critical for successful ITI with AAV8-coF8 liver gene therapy,
and that this process is enhanced by T cell suppression
with rapamycin.
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FIGURE 4 | AAV8-coF8 liver gene transfer enhances anti-mCD20 and rapamycin ITI. BALB/c-HA mice were IV challenged weekly for 4 weeks with 1.5 IU BDD-FVIII
protein and bled at different time points to determine starting Bethesda inhibitor titers. Different groups were established that received vector only (1 × 1011 vg
AAV8-ApoE-hAAT-coF8, n = 7 blue circle), vector and rapamycin (n = 5 inverted purple triangle), vector and anti-mCD20 (n = 5 green triangle), and vector with
anti-mCD20 and rapamycin (n = 8 red square). Vector and anti-mCD20 was administered at week 0 and a second anti-mCD20 at week 3, denoted with black
arrows. Oral gavage with rapamycin was started 2 weeks after vector, three times per week for 4 weeks (green arrows). Summary of experimental timeline (A). Mice
were re-challenged with weekly IV injections of 1.5 IU FVIII starting at week 13 for 4 weeks. All mice received 1 × 1011 vg of the AAV8-coF8 vector by tail vein
injection. Plasma was used to measure anti-FVIII IgG1 levels (B) and Bethesda inhibitor titers (C). The fold reduction in Bethesda inhibitor titers in relation to the
starting titer for each mouse and group were calculated and reported in (D). Values >1 represent a reduction in Bethesda inhibitor titers, 1 no change, and <1 an
increase in Bethesda inhibitor titers. Plasma from 8 weeks post-vector was used to measure anti-AAV8 IgG2a antibody levels by ELISA (E). Representative wells of a
FVIII memory B cell ELISpot assay in which CD138 depleted splenocytes were cultured for 6 days in the absence or presence of 0.1 IU FVIII/mL (F). Colored bars
beneath the wells correspond to the donor group. Statistical analysis of (B,C) was conducted using two-way ANOVA with Tukey’s multiple comparisons test. Groups
with significant differences are annotated a: vector vs. vector-anti-mCD20-rapamycin, b: vector vs. vector-anti-mCD20, and c: vector vs. vector-rapamycin with
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Statistical analysis of (E) was conducted by one-way ANOVA with Tukey’s multiple comparisons test.
DISCUSSION
Despite the successes of recent clinical trials evaluating liver
directed AAV gene therapy for hemophilia A and hemophilia
B, all trial participants to date have been selected based on
gene mutation and history with an absence of inhibitors.
However, a newly proposed clinical study (NCT03734588)
may soon be underway to address the risk of AAV gene
therapy in hemophilia A patients with low titer inhibitors. Pre-
clinical data in mouse, dogs, and non-human primates (NHP)
support immune tolerance induction with AAV-F9 hepatocyte
gene transfer, as this restores expression at its natural site of
synthesis (11, 16). However, inhibitors in hemophilia B patients
undergoing FIX protein therapy is rare with an incidence of 3–
5% (5) and does not likely represent a major complication in
hemophilia B gene therapy.
In contrast, the incidence of inhibitors in hemophilia A
patients is 25–30% meaning that a larger fraction of patients may
be ineligible for gene therapy. This premise is supported by the
increased incidence of inhibitor formation in pre-clinical mouse
and NHP studies following AAV-F8 gene transfer and data from
the present study (11, 38). Despite the fact that hepatocytes can
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express functional FVIII protein, FVIII is naturally synthesized
in endothelial cells, such as liver sinusoidal endothelial cells
therefore expression and secretion in hepatocytes may be
less than optimal (27, 39). Interestingly, pre-clinical data in
hemophilia A mice show effective ITI with in vivo delivery of
a lentiviral vector with FVIII expression restricted to LSECs
(40, 41). It is therefore important to develop protocols to improve
outcomes in high risk and inhibitor positive patients.
Others have reported that AAV-F8 gene transfer in mice and
non-human primates (NHP) often leads to anti-FVIII antibody
formation, attributing this to expression of a human protein
in a different species (42, 43). However, expression of other
human proteins, such as human FIX protein, from AAV liver
gene transfer in mice rarely results in inhibitor formation (14).
Thus, the risk of provoking an immune response against a liver
expressed protein in the context of gene therapy is likely more
dependent on the relative immunogenicity of the transgene (44).
This discrepancy in the tolerogenicity of AAV-F8 and AAV-
F9 liver gene transfer, especially in the context of pre-existing
inhibitors has also been documented by others (38). Data from
two clinical studies in adult hemophilia A patients show that
AAV-F8 gene transfer is safe and effective and thus far no
patients have developed anti-FVIII IgG antibodies and inhibitors.
However, exclusion criteria for these trials eliminates patients
withmutations associated with inhibitor and excludes any patient
that had a history of inhibitor. Thus, it remains unknown how
hemophilia A patients with limited FVIII exposure days or with
inhibitors will respond to AAV8-coF8 gene therapy.
A surprising finding in our study was that BALB/c-HA
and not 129/B6-HA mice treated with an AAV8-coF8 vector
spontaneously developed anti-FVIII IgG1 inhibitors, despite
BALB/c-HA mice having a weaker immune response to
recombinant human BDD-FVIII protein therapy. One potential
explanation is the suggestion that mice on a BALB/c background
have impaired hepatic tolerance following AAV liver gene
transfer (35). However, we have demonstrated that AAV-F9
ITI therapy is highly effective at eliminating inhibitors in
BALB/c-HB mice and can restore hemostasis (16). Gaining an
understanding of why these mice have a differential immune
response toward endogenously expressed BDD-FVIII from AAV
transduced hepatocytes and recombinant BDD-FVIII protein
infusion may therefore help to influence future gene therapy trial
design. An alternative explanation is that the levels of BDD-FVIII
protein provided by AAV gene transfer to hepatocytes in this
study may not be sufficient for tolerance induction. Indeed, for
FIX gene therapy, inhibitor positive BALB/c-HB mice given 1 ×
109, and 1 × 1010 vg AAV8-F9 was insufficient for completely
eliminating inhibitors. Vector dose and antigen levels have been
indirectly and directly tied to an increase in antigen specific
Treg (16, 45), with a small reduction in vector dose shifting the
balance from tolerance to immunity (46). Recent progress with
engineered and hybrid FVIII proteins may help improve BDD-
FVIII transgene levels (47). However, it is presently unclear how
these FVIII variants will be viewed by regulatory agencies and the
immune system (48).
T helper cell dependent antibody formation, which is
responsible for the majority of inhibitors in hemophilia patients,
requires the activation of FVIII specific effector T cells by
professional antigen presenting cells (APC) presenting small
peptide epitopes of FVIII protein. In the presence of antigen,
activated effector T cells, including T follicular helper cells
(TFH) provide critical co-stimulatory signals to promote the
maturation of immature B cells in B cell follicles into high affinity
class switched antibody producing plasma cells. During this
maturation process, a large fraction of these cells become long-
lived antibody producing plasma cells, which exit the follicles
and migrate to the bone marrow. However, a subset of the high
affinity class switched B cells become memory B cells and persist,
providing a pool of primed B cells that can rapidly differentiate
into plasma cells with T cell help and antigen exposure.
Immune suppression protocols combining rapamycin and
anti-CD20 have been used in the clinic to treat refractory
anti-drug antibodies in hemophilia and the lysosomal storage
disorder, Pompe disease (49–53). The immune modulatory
protocol that we employed in this study is designed to be
transient to avoid compromising long-term systemic immunity.
We demonstrated that the most effective immune modulatory
protocol for AAV ITI was the inclusion of both anti-mCD20
and rapamycin. Similar to our previous study evaluating anti-
mCD20 and rapamycin in the context of FVIII protein therapy
(22), we observed an initial decrease in anti-FVIII IgG1 levels
and Bethesda inhibitor titers in both groups that were treated
with anti-mCD20. One potential explanation for these results
is that anti-FVIII IgG1 in our mouse model is likely produced
by both plasmablasts and plasma cells. Thus, we can speculate
that this initial decrease is due to elimination of plasmablasts
which express CD20 and are thus sensitive to depletion with
anti-mCD20. Although elimination of memory B cells played
an important role in the initial reduction in inhibitor titers,
lasting reduction was only achieved in mice that also received
rapamycin, which has been shown to eliminate antigen specific
CD4+ T effector cells while expanding antigen specific Treg (33).
Rapamycin at high doses can also inhibit B cell proliferation
and differentiation, class switching and germinal center responses
(54, 55).
We hypothesized that sustained expression of FVIII protein
from AAV8-F8 transduced hepatocytes would enhance the
effectiveness of ITI when combined with rapamycin and anti-
mCD20. In our prophylactic immune tolerance study (Figure 3)
we demonstrated that immune suppression and AAV8-F8 vector
synergized to prevent inhibitors compared to controls that
received vector alone. When we adoptively transferred Tregs
from different groups of donor mice into naïve BALB/c-HA, only
Tregs from mice receiving immune suppression and vector were
able to suppress antibody formation following re-challenge with
FVIII protein in adjuvant, thus demonstrating that vector derived
FVIII protein was capable of expanding FVIII specific Treg in
the presence of rapamycin. We asked if vector derived FVIII
protein could help improve the effectiveness of our previously
published ITI protocol with rapamycin and anti-mCD20 (22).
The main finding in our previous study was that immune
suppression showed the best outcomes for reducing inhibitor
titers in mice with starting Bethesda inhibitor titers of ∼10
BU/mL. By including gene therapy to the ITI protocol we are now
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able to achieve significant reduction of inhibitors in mice with
an average starting titer of 43 BU/mL, supporting our hypothesis
that combining gene and immune suppressive therapy is an
effective ITI therapy. One limitation of the study was that we were
not able to determine if the improved tolerance from immune
suppression with anti-mCD20 and rapamycin was transient as we
challengedmice with recombinant FVIII protein 7 weeks after the
last rapamycin dosing. Thus, it is possible that hemophilia mice
might not remain refractory to FVIII protein challenge when
there is a longer interval between immune suppression and FVIII
protein challenge.
Immune modulatory therapy targeting both the B and T cell
compartments displayed the best synergy with AAV-F8 ITI in
BALB/c-HAmice with established inhibitors. However, evenwith
adjunct immunotherapy we were unable to completely eliminate
inhibitors and restore hemostasis in contrast to a previous
study reporting inhibitor eradication following AAV8-cF8 gene
transfer in hemophilia A dogs with inhibitor (17). The timing for
elimination of inhibitors in vector treated dogs was dependent
on their peak inhibitors titers and was between 4 and 5 weeks
in animals <10 BU/mL and up to 18 months in a dog with a
peak titer of 216 BU/mL. It is challenging for a similar long-
term follow-up in mice due to their shortened lifespans. Our
study went out to 17 weeks post-vector treatment and after this
time point, we began to lose a substantial number of animals
due to health complications, possibly due to aging or aggression
related injury. Thus, we cannot rule out that inhibitor titers
would have resolved with longer follow-up. However, there are
several differences between our study and the one conducted
in hemophilia A dogs. We used a codon optimized human F8
cDNA compared to a dual vector expressing canine F8 heavy
and light chain. Canine FVIII has been shown to be both better
expressed, have a higher specific activity, and increased stability
as compared to human FVIII (56). Another consideration for
the effectiveness of AAV ITI in hemophilia A is the relative
proportion of long-lived plasma cells, which are CD20 negative,
and thus are refractory to anti-mCD20 depletion. Even though
our treatment was able to deplete memory B cells, long lived
plasma cells are known to maintain serum antibody levels in the
absence of memory B cells (57). One approach to address this
is the inclusion of agents such as AMD3100 (plerixafor) and G-
CSF tomobilize plasma cells from their survival niche in the bone
marrow (58). This combined therapy could potentially increase
the success of ITI and allow the inclusion of inhibitor patients
for FVIII gene therapy. These drugs are commonly used in the
clinic for cancer, autoimmune disease treatment, and to prevent
graft rejection, and therefore are safe and validated. Additionally,
the dose, route of delivery (oral intake vs. IV injection) and
frequency of rapamycin administration could be adjusted to
improve tolerance induction as we have previously found that
daily oral rapamycin was more effective at suppressing inhibitors
in the context of FVIII protein therapy in mice (33).
Finally, we observed that our immune suppressive
combination therapy was also able to suppress development
of AAV capsid specific antibodies. All AAV gene therapy
subjects robustly develop neutralizing antibodies to the viral
vector capsid, which precludes re-administration. This has
implications in hepatic gene therapy for disorders requiring
high expression thresholds, or in pediatric patients with
dividing hepatocytes where transgene expression may be lost
over time. Both rapamycin encapsulated in poly(lactic acid)
nanoparticles or rapamycin + anti-CD20 combination therapy
are currently being evaluated in various pre-clinical models
and human clinical trials for immunomodulation to permit
vector re-administration (50, 51, 59). While our findings are
encouraging, it is necessary to confirm our ELISA results with
the more sensitive in vitro cell based luciferase assay to quantitate
functional anti-AAV neutralizing antibody titers.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
This animal study was reviewed and approved by University
of Florida Institutional Animal Care and Use Committee,
and Indiana University Institutional Animal Care and
Use Committee.
AUTHOR CONTRIBUTIONS
MB and DM designed and coordinated all studies and wrote the
manuscript. MB, BP, SK, JR, and DM conducted experiments for
the study. All authors contributed to the article and approved the
submitted version.
FUNDING
This study was supported by the Bayer Hemophilia Award
Program Early Career Investigator Awards to MB and DM.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.01293/full#supplementary-material
Figure S1 | AAV8-ApoE-hAAT-F9 effectively eradicates inhibitors in hemophilia B
mice on a BALB/c background (BALB/c-F9−/Y or BALB/c-HB). BALB/c-HB mice
(n = 8) were injected weekly with 10 IU FIX protein, week 1 IP and weeks 2–6 IV
and plasma was collected on week 7 for anti-FIX IgG1 measurement by ELISA
(A). Four groups of BALB/c-HB mice (n = 8 per group) were immunized with 1 IU
FIX protein in adjuvant and bled 3 weeks later to measure anti-FIX IgG1 (B),
Bethesda titers (C), and FIX antigen levels (D) in plasma at indicated time points.
Groups are divided into untreated controls (inverted purple triangle) and 2 × 109
vg (green triangle), 1 × 1010 vg (red square), and 1 × 1011 vg (blue circle) and
were followed over time as indicated. Animals received a second challenge with
FIX in adjuvant at week 5 (dotted vertical line). FIX levels reported for naïve
BALB/c-HB mice (orange) or inhibitor reversal mice (blue) injected with 1 × 1011
vg AAV8-ApoE-hAAT-F9 vector (D).
Figure S2 | Anti-mCD20 treated hemophilia A mice lose FVIII memory B cells.
Representative wells of a B cell ELISpot assay with unstimulated and FVIII
stimulated splenocytes (A). Counts of FVIII specific antibody producing cells per 1
× 106 splenocytes (B).
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